Opioids

Five things for pharma marketers to know: Tuesday, January 23, 2018

Five things for pharma marketers to know: Tuesday, January 23, 2018

By

FDA issues new policies for compounded drugs; U.S. doctors test CRISPR on cancer patients for the first time; Palio merged into GSW

Five things for pharma marketers to know: Monday, January 22, 2018

Five things for pharma marketers to know: Monday, January 22, 2018

By

Sanofi to buy Bioverativ for $11.6 billion; Celgene to acquire Juno for $9 billion; Teva to lay off more than 200 in Philadelphia

Five things for pharma marketers to know: Thursday, January 18, 2018

Five things for pharma marketers to know: Thursday, January 18, 2018

By

Senate committee votes in favor of Azar as new HHS head; FDA and DoD launch breakthrough designation program; Walmart offers free opioid disposal solution

Five things for pharma marketers to know: Thursday, January 11, 2018

Five things for pharma marketers to know: Thursday, January 11, 2018

By

Novartis Oncology taps Pfizer exec as CEO; healthcare jobs become the largest source of U.S. employment; HHS nominee wary about drug-pricing negotiations

Five things for pharma marketers to know: Friday, January 5, 2018

Five things for pharma marketers to know: Friday, January 5, 2018

By

Takeda announces deals worth more than $1 billion; biotech and pharma investments reached $10.5 billion in 2017; prescriptions for nerve pain on the rise

Five things for pharma marketers to know: Thursday, December 28, 2017

Five things for pharma marketers to know: Thursday, December 28, 2017

By

Study: male docs earn more than female peers; new Michigan law tackles opioid crisis; study: some docs billed Medicare for most expensive patient visit type

Five things for pharma marketers to know: Friday, December 1, 2017

Five things for pharma marketers to know: Friday, December 1, 2017

By

FDA approves first Apple Watch health accessory; medical charity shared data with pharma donors; FDA approves opioid-addiction treatment

Limits on pharma payments to doctors back on policy menu

Limits on pharma payments to doctors back on policy menu

By

A mini wave of state-level rule-making has thrust the issue of restrictions on pharma payments to medical professionals back into the spotlight.

Five things for pharma marketers to know: Tuesday, November 7, 2017

Five things for pharma marketers to know: Tuesday, November 7, 2017

By

Senator investigates Alkermes' opioid-marketing tactics; FDA approves Roche cancer drugs; CVS to launch next-day delivery nationwide

CDC tells opioid addiction stories with message: 'It only takes a little to lose a lot'

CDC tells opioid addiction stories with message: 'It only takes a little to lose a lot'

By

The CDC has launched the first wave of its awareness campaign about prescription opioids.

Five things for pharma marketers to know: Tuesday, October 31, 2017

Five things for pharma marketers to know: Tuesday, October 31, 2017

By

Pfizer Q3 revenue driven by Prevnar sales; President Trump's opioid panel presents draft to combat crisis; Novartis seeks FDA approval for CAR-T therapy Kymriah

Five things for pharma marketers to know: Monday, October 2, 2017

Five things for pharma marketers to know: Monday, October 2, 2017

By

The FDA tells 75 opioid drugmakers to fund training efforts; epilepsy drug reduces seizure frequency; FDA approves Novo's fast-acting mealtime insulin

Five things for pharma marketers to know: Monday, September 25, 2017

Five things for pharma marketers to know: Monday, September 25, 2017

By

The FDA declines to approve an opioid and a treatment for rheumatoid arthritis; KKR closes WebMD buyout; 60% of teens have received the HPV vaccine

Five things for pharma marketers to know: Friday, September 22, 2017

Five things for pharma marketers to know: Friday, September 22, 2017

By

Express Scripts' Miller says new models needed to pay for CAR-T; FDA warns about Intercept drug deaths; CVS puts limits on opioid scripts

Five things for pharma marketers to know: Monday, September 18, 2017

Five things for pharma marketers to know: Monday, September 18, 2017

By

Insurers rarely require prior authorization for opioids; court of appeals voids J&J win in Advil ads suit; new California law to address drug pricing

Five things for pharma marketers to know: Thursday, August 10, 2017

Five things for pharma marketers to know: Thursday, August 10, 2017

By

One in 12 docs took payments from opioid makers; hospitals cut use of Isuprel and Nitropress after price hikes; AI helping develop ALS drugs

Five things for pharma marketers to know: Tuesday, July 25, 2017

Five things for pharma marketers to know: Tuesday, July 25, 2017

By

Biogen reports better-than-expected Spinraza sales; FDA to discuss opioid prescriptions with payers; UnitedHealth Group launches media review

Five things for pharma marketers to know: Thursday, July 6, 2017

Five things for pharma marketers to know: Thursday, July 6, 2017

By

The FDA suspends three Keytruda studies; drug and device makers gave $8 billion in payments to providers in 2016; Opdivo beat Yervoy in skin-cancer trial

Five things for pharma marketers to know: Thursday, June 22, 2017

Five things for pharma marketers to know: Thursday, June 22, 2017

By

The FDA plans public meeting to encourage generic competition; Mylan reportedly offered rebates to six Medicaid programs; Republicans to present draft bill for Obamacare replacement

Drugmakers must take the lead on opioid epidemic comms, say experts

Drugmakers must take the lead on opioid epidemic comms, say experts

By

Drugmakers are increasingly facing blame from regulators, lawmakers, and the public as the list of lawsuits and investigations at the state and local levels grows.

Five things for pharma marketers to know: Tuesday, May 16, 2017

Five things for pharma marketers to know: Tuesday, May 16, 2017

By

A New York county sues drugmakers over opioid marketing; AstraZeneca files suit against GSK exec; Thermo Fisher acquires biologics firms

Purdue Pharma hires new VP of public affairs, communications

Purdue Pharma hires new VP of public affairs, communications

By

Josephine Martin was previously EVP of public affairs at PhRMA.

Five things for pharma marketers to know: Thursday, April 20, 2017

Five things for pharma marketers to know: Thursday, April 20, 2017

By

Tesaro discloses price for new drug that differs from FDA-approved dosage; uniQure discontinues Glybera; O'Reilly leaves Fox

Pacira, Trinity Health aim to address opioid use in surgeries

Pacira, Trinity Health aim to address opioid use in surgeries

By

Pacira also recently announced a partnership with Johnson & Johnson to co-promote its pain injection for certain surgeries.

Five things for pharma marketers to know: Thursday, March 30, 2016

Five things for pharma marketers to know: Thursday, March 30, 2016

By

Novartis CAR-T drug receives priority review; addiction center's ad compares addiction to cancer; Arizona passes off-label law

Senate committee launches investigation into opioid marketing

Senate committee launches investigation into opioid marketing

By

The committee is seeking information about the companies' sales and marketing strategies.

Five things for pharma marketers to know: Monday, February 13, 2016

Five things for pharma marketers to know: Monday, February 13, 2016

By

Sanofi to sell five OTC drugs to Ipsen; Teva reports 33% revenue growth in Q4; Regeneron issued subpoena about support of nonprofits

Five things for pharma marketers to know: Thursday, December 15, 2016

Five things for pharma marketers to know: Thursday, December 15, 2016

By

Drugmakers promote new type of opioid with unproven results; Heritage execs charged for price-fixing generics; Pershing sells more Valeant shares

Five things for pharma marketers to know: Thursday, October 20, 2016

Five things for pharma marketers to know: Thursday, October 20, 2016

By

Chicago to require pharma reps to track their calls; GlaxoSmithKline joins Instagram; Lilly receives accelerated approval for cancer drug

Five things for pharma marketers to know: Monday, May 16, 2016

Five things for pharma marketers to know: Monday, May 16, 2016

By

Pfizer buys Anacor; Harvard Medical School loosens rules for faculty ties to pharma; Vermont poised to pass price transparency bill